BP
DXCM icon

Ballentine Partners’s DexCom DXCM Stock Holding History

Ballentine Partners’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,279
Closed -$221K – 1028
2025
Q3 		$221K Sell
3,279
-98
-3% -$7.75K ﹤0.01% 865
2025
Q2 		$295K Buy
+3,377
New +$265K ﹤0.01% 697
2025
Q1 		– Sell
-2,762
Closed -$215K – 936
2024
Q4 		$215K Buy
+2,762
New +$204K ﹤0.01% 757
2024
Q3 		– Sell
-2,256
Closed -$256K – 856
2024
Q2 		$256K Sell
2,256
-261
-10% -$33K ﹤0.01% 612
2024
Q1 		$349K Buy
2,517
+266
+12% +$33.4K 0.01% 491
2023
Q4 		$279K Sell
2,251
-902
-29% -$92.1K 0.01% 522
2023
Q3 		$294K Buy
3,153
+694
+28% +$78.2K 0.01% 449
2023
Q2 		$316K Sell
2,459
-766
-24% -$92.6K 0.01% 434
2023
Q1 		$375K Buy
3,225
+940
+41% +$105K 0.01% 368
2022
Q4 		$259K Buy
+2,285
New +$251K 0.01% 415

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ballentine Partners's DXCM Position: Q4 2025 in Review

Ballentine Partners sold out of DexCom (DXCM) in Q4 2025, closing a stake of 3,279 shares — an estimated $221K sold.

Ballentine Partners first reported a position in DXCM in Q4 2022 and held it in 10 quarters. The position peaked at $375K in Q1 2023. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

  • Ballentine Partners reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
  • Ballentine Partners sold 3,279 DexCom shares in Q4 2025, an estimated $221K.
  • Ballentine Partners first reported a position in DexCom in Q4 2022 and held it in 10 quarters.
  • Ballentine Partners's DexCom position peaked at $375K in Q1 2023.
  • 920 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Ballentine Partners's 13F filing for Q4 2025, filed 3 Feb 2026.